53 results about "Apoptosis induction" patented technology

The invention discloses a pharmaceutical composition for reversing pancreatic cancer gemcitabine drug resistance and application of the pharmaceutical composition, and belongs to the technical field of biological medicine. The composition comprises a generic FGFR inhibitor delatinib and gemcitabine, the concentration of the delatinib is 25 to 50 mg / kg, and the concentration of the gemcitabine is 20 to 30 mg / kg. By inhibiting an FGFR2 / FGFR3 signal channel and reducing the expression of FGFR protein in drug-resistant cells, the chemosensitivity of gemcitabine is synergistically enhanced, the apoptosis induction rate is increased by more than two times, and the synergic index (CI) is less than 1. In-vitro and nude mouse transplantation tumor experiments prove that the composition can significantly inhibit the proliferation of gemcitabine drug-resistant pancreatic cancer cells. The Gemcitabine drug-resistant pancreatic cancer drug can be used for preparing a drug for treating Gemcitabine drug-resistant pancreatic cancer with high FGFR3 expression, patients are screened through immunohistochemistry or gene sequencing, intravenous injection or oral administration is adopted, dosage forms comprise freeze-dried powder injection, capsules or tablets, and a new strategy is provided for pancreatic cancer drug-resistant treatment.

The invention particularly relates to a curcumin delivery system based on small extracellular vesicles, a preparation method and application. Curcumin has the defects of poor water solubility, poor chemical stability and insufficient targeting, in order to improve the bioavailability of curcumin, the curcumin delivery system based on small extracellular vesicles provided by the invention adopts RGD peptide surface modified sEVs as a carrier to coat curcumin, and saponin is used for assisting ultrasonic drug loading, so that the drug loading rate of curcumin is improved. According to verification of the invention, the delivery system can effectively improve the in-vitro release performance of the curcumin preparation and realize controlled release and slow release. Meanwhile, the delivery system effectively improves apoptosis induction of curcumin to glioma cells, the blood-brain barrier penetrating capacity of the curcumin delivery system is improved, and the treatment effect on brain glioma is expected to be improved.

The invention relates to the technical field of medicines, and discloses an application of combination of bufalin and heme in preparation of a cancer treatment medicine. According to the invention, by means of an active metabonomics means, a key active metabolite-heme is locked through exogenous library screening and endogenous analysis, and the drug effect of bufalin is regulated by means of the active metabolite. Through verification, it is found that heme can cooperate with the synergistic drug effect in various cancer cell lines, and a new technical normal form based on an active metabolome for improving the drug effect of bufalin is provided. The pharmaceutical composition can improve the apoptosis induction ability of bufalin to different cancer cells, and provides powerful guiding significance for developing a novel treatment scheme in clinical medicine.

The invention belongs to the technical field of medicines, and particularly relates to application of dioscin combined with chidamide in diffuse large B-cell lymphoma. Specifically, research finds that the dioscin can significantly inhibit DLBCL cell proliferation and induce cell cycle arrest and apoptosis by up-regulating PINK1 / Parkin mediated mitochondrial autophagy and enhancing H3K27 acetylation mediated epigenetic regulation. When the chidamide and the dioscin are combined for use, a synergistic effect can be generated, and by further increasing the H3K27ac level, the cell apoptosis induction effect is enhanced, and the in-vivo and in-vitro anti-tumor activity on DLBCL is remarkably improved. The invention provides a novel and efficient DLBCL combined treatment scheme, and provides a new pharmaceutical composition and theoretical support for clinical diagnosis and treatment of DLBCL, so that the application has good practical application value.

The present disclosure relates to apoptosis-induced stem cells, a method for producing the same, and a pharmaceutical composition for the prevention or treatment of an inflammatory disease or a renal disease, including the same. Cells according to an aspect and a composition including the cells as an active ingredient have an increased IL-10 expression level without including a cryoprotectant, and thus can be effectively used for the prevention or treatment of an inflammatory disease or a renal disease.

The invention relates to a stem cell bioactive nano-vesicle with efficient inflammation regulation and tissue repair effects, the average particle size of the nano-vesicle is 100-350nm, the polydispersity index (PDI) is 0.05-0.40, and the expression rate of phosphatidylserine (PS) on the surface of the nano-vesicle is greater than 40%. According to the preparation method, stem cells are subjected to apoptosis induction, and then a programmed serial extrusion process is adopted to prepare the nano-vesicles. The nano vesicles are moderate in particle size, uniform in distribution and high in production efficiency, the preparation process is easy to operate, the quality is stable and controllable, and the nano vesicles have excellent technical effects in the aspects of repair and regeneration of inflammation injury type tissues and organs.

The invention belongs to the technical field of biological pharmacy, and particularly relates to polylysine nanoparticles for delivering oxaliplatin and a preparation method of the polylysine nanoparticles. The invention discloses a preparation method of polylysine nanoparticles for delivering oxaliplatin. The polylysine nanoparticles are applied to preparation of a tumor targeting drug mPssPC-OXA NPs with small particle size, positive surface charge and excellent stability. The mPssPC-OXA NPs can respond to a tumor microenvironment with high GSH concentration to quickly release a drug, and shows an excellent HCT-116 cell uptake effect and an effective RAW264.7 cell immune escape effect in an in-vitro anti-colon cancer cell test. In addition, the mPssPC-OXA NPs also shows more remarkable cytotoxicity, cell migration inhibition, cell proliferation inhibition and HCT-116 cell apoptosis induction effects compared with free OXA.

The invention provides a personalized cancer vaccine based on apoptosis vesicles and a preparation method and application thereof, and belongs to the technical field of biological medicine, the personalized cancer vaccine comprises apoptosis vesicles, an immunologic stimulant and a biocompatibility carrier; the apoptosis vesicles are extracellular vesicles generated after tumor cells are subjected to apoptosis induction; the biocompatible carrier is a modified chitosan hydrogel, and the biocompatible carrier is a modified chitosan hydrogel; the immunologic stimulant is loaded in the apoptosis vesicle, and the apoptosis vesicle loaded with the immunologic stimulant is embedded into the modified chitosan hydrogel. According to the invention, apoptosis vesicles generated by induction of tumor cells of a patient are taken as a core, the apoptosis vesicles have a natural tumor antigen library and a strong immune activation capability, and personalized precise treatment can be realized; meanwhile, the invention provides a preparation method and application in postoperative tumor recurrence prevention and treatment, and provides technical support for clinical transformation.

The present application relates to a method for preparing a dendritic cell for producing a T cell adapter, comprising the steps of: preparing a nucleic acid construct encoding a multispecific T cell adapter comprising a first antigen binding domain and a second binding domain for specifically binding to CD3 on the surface of a T cell to activate the T cell, the second binding domain is an apoptosis inducing ligand TRAIL; and transferring the nucleic acid construct as an exogenous nucleic acid into the DC cell to obtain the dendritic cell for generating the T cell adapter. The dendritic cell for generating the T cell adapter can assist a human immune system in better and more targeted killing of tumor cells.

Provided is a fusion protein comprising a polypeptide component that blocks binding of CD47 to SIRP alpha and a polypeptide that binds to and triggers a TRAIL receptor or Fas. Also provided is a method of treating cancer in a patient comprising administering the fusion protein of the invention to a patient in need of such treatment.

The invention discloses skin mucosa maintenance liquid capable of killing fungi and HPV (human papillomavirus) as well as a preparation method and application of the skin mucosa maintenance liquid, and belongs to the technical field of sterilization and virus removal. The skin mucosa maintenance liquid is prepared from octanol ether, benzalkonium bromide, phenoxyethanol, yermate, parachlorometaxylenol, taetinic acid, chitosan, keratinase, fluconazole, glycerol, borneol, menthol, absolute ethyl alcohol and tween-40. Wherein the skin mucosa maintenance liquid has an effect of regulating apoptosis induction on abnormal cells and an effect on vaginal flora, and has an obvious inhibition effect on cervicitis and colpitis mycotica, namely an anti-inflammatory effect; meanwhile, apoptosis of cells containing HPV16 and HPV18 genes can be induced, shedding of abnormal cells is promoted, diseased cells are killed, and vaginal tissues with pathological changes are removed.

The invention discloses a thiosemicarbazone compound containing a naphthyl structure as well as a preparation method and application of the thiosemicarbazone compound. The thiosemicarbazone compound has biological activity on human breast cancer cells. The anti-tumor activity of the compound is verified through in-vitro experiments, including an inhibition effect experiment of the compound on proliferation of human breast cancer cells, an influence experiment on oxidative stress level of the breast cancer cells, an influence experiment on mitochondrial membrane potential of the breast cancer cells and an experiment for inducing apoptosis of the breast cancer cells. The thiosemicarbazone compound containing the naphthyl structure has remarkable anti-tumor activity, can effectively inhibit proliferation of human breast cancer cells, can remarkably improve the oxidative stress level of the breast cancer cells in a concentration-dependent mode, and has a close correlation between the regulation effect on the mitochondrial membrane potential of the breast cancer cells and the treatment concentration; the compound can effectively induce apoptosis of breast cancer cells, has excellent anti-breast cancer activity, and provides important candidate compounds and theoretical basis for research and development of novel anti-tumor drugs.

The present disclosure relates to apoptosis-induced stem cells, a method for producing the same, and a pharmaceutical composition for the prevention or treatment of an inflammatory disease or a renal disease, including the same. Cells according to an aspect and a composition including the cells as an active ingredient have an increased IL-10 expression level without including a cryoprotectant, and thus can be effectively used for the prevention or treatment of an inflammatory disease or a renal disease.

The invention discloses a tumor cell proliferation inhibition physiotherapy device and method based on a specific-intensity micro magnetic field, and belongs to the field of medical instruments.The tumor cell proliferation inhibition physiotherapy device comprises a main board, a rear board is fixed to the rear portion of the upper surface of the main board, a front board is rotatably connected to the front end of the main board, and the left side and the right side of the main board are each provided with two rotating grooves; the universal wheels are arranged at the bottom and matched with a handle of the rear plate, so that flexible pushing can be achieved, the moving direction can be controlled, and transferring is convenient and fast; a folding structure is provided, the support can be driven to retract by turning over the side plates and the front plate, the size of the device is reduced, meanwhile, physiotherapy equipment can be wrapped and protected, losses in the transportation and storage process are reduced, and space is saved; the physiotherapy equipment generates a 1-100mT specific intensity micro magnetic field through current, and cooperates with a warm effect to inhibit tumor cell proliferation from multiple aspects of cell cycle interference, energy metabolism destruction and apoptosis induction, so that the physiotherapy effect is ensured.

The invention discloses an application of brucein D and Vinetoram in preparation of a medicine for treating acute or drug-resistant myelogenous leukemia. Through a large number of experimental screening, the brucein D and the Venotocork are combined for medication, and the test result shows that the brucein D and the Venotocork act on different targets and different signal channels of AML cells to generate a remarkable synergistic anti-tumor effect, and after the brucein D and the Venotocork are combined, the proliferation inhibition and apoptosis induction effects on the AML cells can be directly enhanced, and the anti-tumor effect of the Venotocork D and the AML cells can be improved. The compound can also reverse the drug resistance possibly occurring when the Vinetoram is singly used, and also has a remarkable killing effect on chemotherapy drug-resistant AML cells at the same time. The composition provided by the invention can reduce the dosage of antitumor drugs, reduce drug resistance, reduce adverse reactions and improve the life quality of patients, and has important application prospects.

The invention relates to stem cell-derived engineered nano-vesicles (e-NVs) for promoting hair growth, the engineered nano-vesicles are prepared from stem cells through engineering induction, apoptosis induction and programmed serial extrusion processes in sequence, and an inducer used for engineering induction is 3, 3 '-diindolylmethane. The particle size of the engineered nano vesicle is mainly distributed in a range of 50-300 nm, the polydispersity coefficient is 0.05-0.20, and the expression proportion of phosphatidylserine is 40%-50%. The rice vesicles can effectively improve the hair follicle microenvironment, adjust the hair growth cycle, promote proliferation and differentiation of hair follicle stem cells and remarkably increase the hair regeneration rate of androgenetic alopecia model mice, and a safe, convenient and efficient clinical strategy is provided for hair regeneration treatment.

This invention relates to the field of biomedical technology, and more particularly to a method for preparing mesenchymal stem cell apoptotic vesicles. The method primarily employs serum-free culture medium for 3D microsphere culture of stem cells, followed by induction of apoptosis into apoptotic vesicles using an apoptosis induction system, resulting in highly efficient apoptotic vesicles. This method significantly enhances the bidirectional immunomodulatory effect of stem cell-derived apoptotic vesicles, greatly expanding the application range and therapeutic efficacy of these vesicles. The serum-free culture medium avoids the safety risks and batch-to-batch variations associated with traditional culture media, and significantly improves the proliferation capacity, passage stability, and immunomodulatory effect of stem cells, enabling stable and efficient acquisition of apoptotic vesicles.

The invention relates to the technical field of biological medicines, and particularly discloses a cancer suppression small interfering RNA (Ribonucleic Acid) capable of simultaneously targeting cancer genes PTTG1 and STMN1 and application of the cancer suppression small interfering RNA, and the technical key points are as follows: the positive-sense strand sequence of the small interfering RNA is GGGAGAUCUCAAGUUUCAATT, and the antisense strand sequence of the small interfering RNA is UUGAAACUUGAGAUCUCCCTT. The small interfering RNA provided by the invention can specifically silence the expression of PTTG1 and STMN1 at the same time. Compared with siRNA (such as siRNA for ASCC3 or TRAPPC4) targeting a single gene in the prior art, the siRNA provided by the invention has the advantages that synergistic inhibition on tumor proliferation and metastasis pathways is realized through double-targeting design, and the inhibition effect on tumor cell growth is more remarkable; compared with a method of physically mixing two single siRNAs, the method provided by the invention has higher cell apoptosis induction efficiency and better in-vivo tumor inhibition effect; the small interfering RNA is effective in various liver cancer cells, has a lasting effect in an animal model, and provides a core molecular entity for developing novel antitumor drugs.

The application belongs to the technical field of medicine, and particularly relates to paclitaxel / molybdenum boride nanomaterial and a preparation method and application thereof. 4 / 3 B 2‑x Nanosheet material, the material improves the stability of Mo 4 / 3 B 2‑x Nanosheet by introducing soybean phospholipid, has the characteristics of simple preparation, high drug loading rate and high photo-thermal conversion efficiency. After the nanomaterial loads paclitaxel, as a dual-functional nanodrug for chemotherapy and photo-thermal therapy, when used for lung adenocarcinoma cells, the apoptosis of cancer cells is induced, and the induction effect is better than that of Taxol and Mo 4 / 3 B 2‑x +IR alone. When the nanodrug is applied to a mouse lung cancer model, the growth of the tumor is significantly inhibited, and the inhibition effect is better than that of Taxol and Mo 4 / 3 B 2‑x +IR alone. The results show that the Taxol / Mo 4 / 3 B 2‑x Nanosheet has a synergistic effect when used for lung cancer treatment.

The invention discloses engineered mitochondria as well as a preparation method and application thereof. The preparation method of the engineered mitochondria comprises the following steps: constructing immortalized mesenchymal stem cells; separating and extracting mitochondria from the immortalized mesenchymal stem cells; taking the immortalized mesenchymal stem cells, carrying out IFN-gamma and TNF-alpha pretreatment on the immortalized mesenchymal stem cells, carrying out apoptosis induction, and extracting to obtain an engineered apoptotic extracellular vesicle membrane; mitochondria and the engineered apoptotic extracellular vesicle membrane are mixed, and after ultrasonic treatment and centrifugation, engineered mitochondria with the engineered apoptotic extracellular vesicle membrane coated on the surface is obtained; the engineering mitochondria has the advantages that the stability and the targeting property of the engineering mitochondria are effectively improved, the problem of low cell uptake efficiency during direct transplantation of the mitochondria is solved, the function recovery effect of the mitochondria in damaged cells is enhanced, and a more efficient and stable mitochondria source is provided for transplantation treatment of the engineering mitochondria.

The disclosure provides synthetic cytotoxic cells, comprising a hydrogel microsphere and a TNF-related apoptosis-inducing ligand (TRAIL), or active fragment thereof. In aspects, the TRAIL or active fragment thereof is attached to the surface of the hydrogel microsphere. The disclosure further provides methods of preparing the synthetic cytotoxic cells and methods of use thereof in the treatment of cancer.

The application discloses application of convallatoxin in preparation of a medicine for resisting prostate cancer and belongs to the technical field of biological medicines. The application finds that the convallatoxin has the efficacy of resisting prostate cancer, and the increase of UPP1 expression can enhance the inhibiting effect or the apoptosis induction effect of the convallatoxin on prostate cancer cells. Compared with the group of using the convallatoxin alone, after the 22Rv1 cells overexpressing UPP1 are treated by the convallatoxin, the apoptosis rate of the cells is increased by about 4 times, which indicates that the increase of UPP1 expression can enhance the effect of the convallatoxin on inducing the apoptosis of the prostate cancer cells.

The application discloses a preparation method of a bone formation inducing biological additive based on red blood cell-derived apoptotic vesicles and application thereof, and the preparation method comprises the following steps: a, red blood cell apoptosis induction treatment; b, collection and purification of red blood cell-derived apoptotic vesicles RBC-ApoEVs through series differential ultracentrifugation; c, characterization and quality control of the apoptotic vesicles; d, acquisition, culture and basic identification of SHED; and e, determination of 0.5 mu g / mL as the optimal bone formation inducing synergistic concentration of the red blood cell-derived apoptotic vesicles RBC-ApoEVs. The bone formation inducing biological additive prepared by the preparation method can be used as a safe and efficient bone formation inducing synergistic agent, and can solve the problem that "proliferation promotion" and "differentiation promotion" are difficult to be coordinated, and can also avoid the dependence on exogenous growth factors and related risks. The bone formation inducing biological additive can be applied to in-vitro induction of SHED bone differentiation, bone regeneration cell suspension and bone tissue engineering compound.

The purpose of the present invention is to provide a novel means that targets M1 microglia and is useful for the treatment of central nervous system diseases and the like. Provided is an M1 microglia-targeting fusion peptide in which an M1 microglia-targeting peptide and an apoptosis-inducing peptide are directly or indirectly linked to each other, wherein the M1 microglia-targeting peptide is a peptide mentioned in (1) or (2): (1) a peptide which has a structure such that at least one cysteine residue is directly linked to each of both ends of the amino acid sequence represented by HHSSSAR (SEQ ID NO: 1) or an amino acid sequence formed by linking a plurality of the sequences; and (2) a peptide which comprises an amino acid sequence having a structure such that one amino acid residue is or a plurality of amino acid residues are deleted, substituted or added in the amino acid sequence for the peptide (1) and which targets M1 microglia.

The present application provides multispecific antigen-binding proteins (e.g., antibodies) that specifically bind TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin 17 (CDH17). The application also provides conjugates comprising the multispecific antigen-binding proteins, polynucleotides and recombinant vectors encoding the multispecific antigen-binding proteins, as well as host cells and methods for preparing the multispecific antigen-binding proteins. The application further provides pharmaceutical compositions comprising the multispecific antigen-binding proteins andmethods for treating a disease or disorder using the multispecific antigen-binding proteins.

The present disclosure relates to apoptosis-induced stem cells, a method for producing the same, and a pharmaceutical composition for the prevention or treatment of an inflammatory disease or a renal disease, including the same. Cells according to an aspect and a composition including the cells as an active ingredient have an increased IL-10 expression level without including a cryoprotectant, and thus can be effectively used for the prevention or treatment of an inflammatory disease or a renal disease.

The invention relates to a stem cell nano-vesicle with a synergistic repairing effect, the stem cell nano-vesicle is prepared by sequentially and continuously performing hypoxia treatment, apoptosis induction and programmed series extrusion on stem cells, the average particle size of the stem cell nano-vesicle is 100-300nm, the polydispersity index is 0.05-0.30, the average particle size is 100-300nm, the average particle size is 100-300nm, the average particle size is 1-10nm, the average particle size is 1-10nm, and the stem cell nano-vesicle has a synergistic repairing effect. The expression rate of phosphatidylserine on the surface of the vesicle is greater than 40%. The stem cell nano-vesicle can promote endothelial cell migration and angiogenesis and maturation, can induce M1 type proinflammatory macrophages to be polarized into M2 type anti-inflammatory macrophages, and can release and repair cell factors in a large quantity. Compared with exosomes and other known nano-vesicles, the stem cell nano-vesicle disclosed by the invention has stronger functions of promoting angiogenesis, regulating immunity and repairing.

The present invention relates to the use of luteolin to enhance the sensitization of cisplatin in the preparation of a drug for the treatment of esophageal squamous cell carcinoma. The present invention finds that luteolin can block the progression of esophageal squamous cell carcinoma cells in multiple aspects, including apoptosis induction, growth inhibition, and invasion inhibition. Luteolin can also significantly enhance the ability of cisplatin to inhibit the lymphatic metastasis of esophageal squamous cell carcinoma cells in a mouse model, demonstrating a significant synergistic effect between the two.

The invention discloses application of a (+)-JQ1 and Pracinostat pharmaceutical composition in preparation of a medicine for treating cervical cancer, and belongs to the technical field of biological medicines. The pharmaceutical composition comprises a BET inhibitor (+)-JQ1 and an HDAC inhibitor Pracinostat in effective treatment dose, a cervical cancer cell model is utilized, the anti-cervical cancer cell effect of the (+)-JQ1 combined with the Pracinostat is evaluated on the cellular level, the result shows that the synergistic index of the (+)-JQ1 combined with the Pracinostat for killing tumor cells is 15.079, the pharmaceutical composition has remarkable synergistic proliferation inhibition and apoptosis induction effects, and the pharmaceutical composition is suitable for clinical application. The effect is far better than that of single-drug treatment. The (+)-JQ1 and Pracinostat combination provided by the invention shows the activity of cooperatively killing cervical cancer cells, and has a wide prospect of being developed into drugs for treating cervical cancer.

The application discloses a compound drug-loaded exosome for overcoming cancer TRAIL drug resistance and a preparation method thereof, relates to the technical field of compound nano-drug preparation, and comprises an engineered exosome and an interfering RNA targeting a natriuretic peptide receptor A gene, wherein the engineered exosome is derived from a cell capable of expressing a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and carries the TRAIL protein; the interfering RNA is loaded in the engineered exosome; and the engineered exosome and the interfering RNA synergistically act to silence the NPRA gene through the interfering RNA to overcome the drug resistance of cancer cells to TRAIL. The application can silence the NPRA gene and remodel the apoptosis sensitivity of tumor cells through multiple channels, thereby efficiently overcoming the TRAIL drug resistance.